, Volume 47, Issue 6, pp 855–861

Sepsis Management and Antiendotoxin Therapy after Nebacumab

A Reappraisal
  • James C. Hurley
Leading Article


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Annals of Internal Medicine 60: 759–776, 1964PubMedGoogle Scholar
  2. Barclay ML, Begg EJ, Chambers ST. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrobial Agents and Chemotherapy 36: 1951–1957, 1992PubMedCrossRefGoogle Scholar
  3. Baumgartner JD, Heumann D, Gerain J, et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS induced tumor necrosis factor a and interleukin 6: comparison of O side chain-specific antibodies with core LPS antibodies. Journal of Experimental Medicine 171: 889–896, 1990PubMedCrossRefGoogle Scholar
  4. Bone RC, Fisher Jr CJ, Clemmer TP, et al. Acontrolled trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine 317: 653–658, 1987PubMedCrossRefGoogle Scholar
  5. Brandtzaeg P, Kierulf P, Gaustad P, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. Journal of Infectious Diseases 159: 195–204, 1989PubMedCrossRefGoogle Scholar
  6. Calandra T, Baumgartner J-D, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Journal of Infectious Diseases 161: 982–987, 1990PubMedCrossRefGoogle Scholar
  7. Cartwright K, Reilly S, White D, et al. Early treatment with parenteral penicillin in meningococcal disease. British Medical Journal 305: 143–147, 1992PubMedCrossRefGoogle Scholar
  8. Chong K-T, Huston M. Implications of endotoxin contamination in the evaluation of antibodies to lipopolysaccharides in a murine model of gram negative sepsis. Journal of Infectious Diseases 156: 713–719, 1987PubMedCrossRefGoogle Scholar
  9. Cohen J, Glauser MP. Septic shock: treatment. Lancet 338: 736–739, 1991PubMedCrossRefGoogle Scholar
  10. Cox CE, Harrison LH. Comparison of gentamicin and polymyxin-B-kanamycin in therapy of bacteremia due to gram negative bacilli. Journal of Infectious Diseases 124 (Suppl.): S156–163, 1971PubMedCrossRefGoogle Scholar
  11. Cross AS, Opal SM, Palardy JE, et al. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. Journal of Infectious Diseases 167: 112–118, 1993PubMedCrossRefGoogle Scholar
  12. Cross AS, Opal SM, Sadoff JC, et al. Choice of bacteria in animal models of sepsis. Infection and Immunity 61: 2741–2747, 1993PubMedGoogle Scholar
  13. Danner RL, Eichacker PQ, Doerfler ME, et al. Therapeutic trial of lipid X in a canine model of septic shock. Journal of Infectious Diseases 167: 378–384, 1993PubMedCrossRefGoogle Scholar
  14. Danner RL, Elin RJ, Hosseini JM, et al. Endotoxemia in human septic shock. Chest 99: 169–175, 1991PubMedCrossRefGoogle Scholar
  15. Editorial. Endotoxaemia or endotoxinaemia? Lancet 340: 1323, 1992Google Scholar
  16. Fisher Jr CJ, Opal SM, Dhainaut JF, et al. Influence of an anti-tumour necrosis factor antibody on cytokine levels in patients with sepsis. Critical Care Medicine 21: 318–327, 1993PubMedCrossRefGoogle Scholar
  17. Flynn PM, Shenep JL, Gigliotti F, et al. Immunolabelling of lipopolysaccharide liberated from antibiotic-treated Escherichia coli. Infection and Immunity 56: 2760–2762, 1988PubMedGoogle Scholar
  18. Flynn PM, Shenep JL, Stokes DC, et al. Effect of methylprednisolone on bacterial clearance and endotoxin liberation during experimental sepsis induced by Gram-negative bacteria. Infection and Immunity 52: 26–30, 1986PubMedGoogle Scholar
  19. Flynn PM, Shenep JL, Stokes DC, et al. Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicemia. Journal of Infectious Diseases 156: 706–712, 1987PubMedCrossRefGoogle Scholar
  20. Glauser MP, Zanetti G, Baumgartner J-D, et al. Septic shock: pathogenesis. Lancet 338: 732–736, 1991PubMedCrossRefGoogle Scholar
  21. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. Journal of the American Medical Association 266: 1097–1102, 1991PubMedCrossRefGoogle Scholar
  22. Hoffman WD, Pollack M, Banks SM, et al. Distinct functional activities in canine septic shock of monoclonal antibodies specific for the O-polysaccharide and core regions of Escherichia coli lipopolysaccha-ride. Journal of Infectious Diseases 169: 553–561, 1994PubMedCrossRefGoogle Scholar
  23. Hoffman SL, Punjabi NH, Kumala S, et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dex-amethasone. New England Journal of Medicine 310: 82–88, 1984PubMedCrossRefGoogle Scholar
  24. Horton R. Voluntary suspension of Centoxin. Lancet 341: 298, 1993CrossRefGoogle Scholar
  25. Hurley JC. Antibiotic-induced release of endotoxin: a reappraisal. Clinical Infectious Diseases 15: 840–854, 1992PubMedCrossRefGoogle Scholar
  26. Hurley JC. Clinical effects and therapy of endotoxaemia. Correspondence. British Journal of Surgery 80: 809, 1993aCrossRefGoogle Scholar
  27. Hurley JC. Reappraisal of the role of endotoxin in the sepsis syndrome. Lancet 341: 1133–1135, 1993bPubMedCrossRefGoogle Scholar
  28. Hurley JC. Gram negative sepsis: what dilemma? Correspondence. Clinical Microbiology Reviews 6: 443, 1993cPubMedGoogle Scholar
  29. Hurley JC. Self administration of Salmonella endotoxin. Correspondence. New England Journal of Medicine 329: 1426–1427, 1993dCrossRefGoogle Scholar
  30. Hurley JC. Bacteremia, endotoxemia and mortality in gram negative sepsis: a reappraisal. Correspondence. Journal of Infectious Diseases 168: 246–247, 1993eCrossRefGoogle Scholar
  31. J-5 Study Group. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double blind trial. Journal of Infectious Diseases 165: 695–701, 1992CrossRefGoogle Scholar
  32. Martin CM, Cuomo AJ, Geraghty MJ, et al. Gram negative rod bacteremia. Journal of Infectious Diseases 119: 506–517, 1969PubMedCrossRefGoogle Scholar
  33. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 155: 93–99, 1987PubMedCrossRefGoogle Scholar
  34. O’Brien AD, Weinstein DA, Soliman MY, et al. Additional evidence that the Lps gene locus regulates natural resistance to Styphimurium in mice. Journal of Immunology 134: 2820–2823, 1985Google Scholar
  35. Opal SM, Sadoff JC, Fisher CJ, et al. Initial findings of the interleukin-1 receptor antagonist (IL-Ira) phase III trial in patients with severe sepsis. International Conference on Antimicrobial Agents and Chemotherapy 1993. Abstract no. 20, American Society for Microbiology, Washington, DC, 1993Google Scholar
  36. Peduzzi P, Shatney C, Sheagren J, Sprung C, and The Veterans Affairs Systemic Sepsis Cooperative Study Group. Predictors of bacteremia and Gram-negative bacteremia in patients with sepsis. Archives of Internal Medicine 152: 529–535, 1992PubMedCrossRefGoogle Scholar
  37. Quezado ZMN, Natanson C, Alling DW, et al. A controlled trial of HA-1A in a canine model of Gram-negative septic shock. Journal of the American Medical Association 269: 2221–2227, 1993PubMedCrossRefGoogle Scholar
  38. Strang JR, Pugh EJ. Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital. British Medical Journal 305: 141–143, 1992PubMedCrossRefGoogle Scholar
  39. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. New England Journal of Medicine 317: 659–665, 1987CrossRefGoogle Scholar
  40. Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. New England Journal of Medicine 326: 1153–1157, 1992PubMedCrossRefGoogle Scholar
  41. Woods JP, Black JR, Barritt DS, et al. Resistance to meningococcemia apparently conferred by anti-H.8 monoclonal antibody is due to contaminating endotoxin and not to specific immunoprotection. Infection and Immunity 55: 1927–1928, 1987PubMedGoogle Scholar
  42. Wortel CH, von der Möhlen MAM, van Deventer SJH, et al. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in Gram-negative sepsis: relationship to endotoxin and cytokine levels. Journal of Infectious Diseases 166: 1367–1374, 1992PubMedCrossRefGoogle Scholar
  43. Ziegler EJ. Protective antibody to endotoxin core: the emperor’s new clothes?. Journal of Infectious Diseases 158: 286–290, 1988PubMedCrossRefGoogle Scholar
  44. Ziegler EJ, Fisher Jr CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. New England Journal of Medicine 324: 429–436, 1991PubMedCrossRefGoogle Scholar
  45. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medicine 307: 1225–1230, 1982PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • James C. Hurley
    • 1
  1. 1.Division of Infectious DiseasesChildren’s Hospital & Medical CenterSeattleUSA

Personalised recommendations